Subcutaneous versus intravenous daratumumab in multiple myeloma

被引：0
|
作者：
Shibusawa, Motoharu [1 ]
Tanimoto, Tetsuya [2 ]
机构：
[1] Shinmatsudo Cent Gen Hosp, IMS Grp, Dept Hematol, Chiba 2700034, Japan
[2] Navitas Clin Kawasaki, Kawasaki, Kanagawa, Japan
来源：
LANCET HAEMATOLOGY | 2020年 / 7卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E558 / E558
页数：1
相关论文
共 50 条
  • [1] Subcutaneous versus intravenous daratumumab in multiple myeloma reply
    Mateos, Maria-Victoria
    Usmani, Saad Z.
    [J]. LANCET HAEMATOLOGY, 2020, 7 (08): : E559 - E559
  • [2] Safety of Subcutaneous Daratumumab/ Hyaluronidase after Intravenous Daratumumab for Patients with Multiple Myeloma
    Copley, Melissa
    Metheny, Leland
    Klisovic, Rebecca B.
    Malek, Ehsan
    [J]. BLOOD, 2022, 140 : 13202 - 13203
  • [3] Daratumumab subcutaneous formulation for the treatment of multiple myeloma
    Paul, Barry
    Hamadeh, Issam
    Atrash, Shebli
    Bhutani, Manisha
    Voorhees, Peter
    Usmani, Saad Z.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (11) : 1253 - 1259
  • [4] An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma
    Paul, Barry
    Atrash, Shebli
    Bhutani, Manisha
    Voorhees, Peter
    Hamadeh, Issam
    Usmani, Saad Z.
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (08) : 795 - 802
  • [5] Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma
    Slavcev, Mary
    Spinelli, Allison
    Absalon, Elisabeth
    Masterson, Tara
    Heuck, Christoph
    Lam, Annette
    De Cock, Erwin
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 465 - 473
  • [6] Interim Results of a Time and Motion Survey Regarding Subcutaneous Versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma
    Slavcev, Mary
    Spinelli, Allison
    Absalon, Elisabeth
    Masterson, Tara
    Heuck, Chris
    Lam, Annette
    De Cock, Erwin
    [J]. BLOOD, 2020, 136
  • [7] Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Multiple Myeloma Patients at Mayo Clinic
    Soefje, Scott
    Carpenter, Corinne
    Carlson, Katherine
    Awasthi, Samir
    Lin, Thomas S.
    Kaila, Shuchita
    Tarjan, Daniel
    Kayal, Nikhil
    Kirkup, Christian
    Wagner, Tyler
    Gray, Kathleen
    Kumar, Shaji
    [J]. BLOOD, 2021, 138
  • [8] Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
    Usmani, Saad Z.
    Nahi, Hareth
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Chari, Ajai
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Hellemans, Peter
    Masterson, Tara
    Clemens, Pamela L.
    Luo, Man
    Liu, Kevin
    San-Miguel, Jesus
    [J]. BLOOD, 2019, 134 (08) : 668 - 677
  • [9] Multiple Myeloma: Extension of Approval for subcutaneous Administration of Daratumumab
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (7-8) : 397 - 397
  • [10] Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
    Yamaoka, Kenta
    Irie, Kei
    Hiramoto, Nobuhiro
    Hirabatake, Masaki
    Ikesue, Hiroaki
    Hashida, Tohru
    Shimizu, Tadashi
    Ishikawa, Takayuki
    Muroi, Nobuyuki
    [J]. INVESTIGATIONAL NEW DRUGS, 2023, 41 (05) : 761 - 767
12345